IDIOPATHIC PULMONARY FIBROSIS

This phase 3 trial tests whether the oral drug rentosertib (INS018_055) can slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. About 320 participants will receive either rentosertib or a placebo daily for 52 weeks. The main …

This Phase II trial tests whether a combination of therapeutic plasma exchange (filtering the blood), rituximab (a drug that targets certain immune cells), and intravenous immunoglobulin (IVIg) can slow lung decline in people with progressive idiopathic pulmonary fibrosis (IPF). …

This study tests an experimental tablet called SYH2059 in 156 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants will receive either the drug or a placebo to see if it can slow the decline in lung function. The…

This study tests whether metformin, a standard diabetes medicine, can slow the worsening of idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 400 high-risk patients will receive either metformin or a placebo. The goal is to see if metformin can delay death, hospi…

People with interstitial lung disease (ILD) can suddenly get much worse, but it is hard to tell if the cause is a lung flare-up or a blood clot in the lungs (pulmonary embolism). This observational study will follow 70 adults with ILD who come to the hospital with worsening breat…

This study is testing whether an integrated precision medicine platform can improve how doctors diagnose and manage chronic inflammatory lung diseases like COPD and idiopathic pulmonary fibrosis. Researchers will collect blood and saliva samples for biomarker analysis, monitor in…

This study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The fi…

This phase 1 trial tests a new investigational drug, SCB0020160, for the first time in humans. Healthy adult men aged 18 to 65 receive either the drug or a placebo to evaluate safety, tolerability, and how the drug moves through the body. The study also looks at whether food affe…

This observational study will collect data from 1000 people with idiopathic pulmonary fibrosis (IPF) across multiple Italian centers. Researchers will use machine learning to build a model that predicts disease progression, acute flare-ups, and response to treatment. The goal is …